logo
  

Biogen, AbbVie Voluntarily Withdraw Worldwide MA For ZINBRYTA - Quick Facts

Biopharmaceutical firms Biogen, Inc. (BIIB) and AbbVie (ABBV) announced Friday the voluntary worldwide withdrawal of ZINBRYTA as a treatment for relapsing multiple sclerosis.

The companies believe that characterizing the complex and evolving benefit/risk profile of ZINBRYTA will not be possible going forward given the limited number of patients being treated.

Biogen will continue to work collaboratively with regulatory authorities in the withdrawal of product and with healthcare providers worldwide in their support of ZINBRYTA patients.

Patients currently treated with ZINBRYTA should contact their healthcare provider if they have any questions or concerns.

ZINBRYTA (daclizumab) is currently available in the EU, U.S., Switzerland, Canada and Australia.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla Inc. founder and CEO Elon Musk has sold some of his stake in the luxury electric car maker to avoid an emergency sale of its stock in the event of a forceful Twitter deal. Twitter Inc. and Tesla shares were gaining more than 4 percent in the pre-market activity on the NYSE and Nasdaq, respectively, following the news. Meta Platforms Inc., the parent of Facebook, Instagram, and WhatsApp, has added three more new privacy features to WhatsApp in its bid to enhance control and privacy on the popular messaging app. These features will give the user more control over their messages with added interlocking layers of protection. Insurance company Prudential plc reported Wednesday a sharp drop in first-half pre-tax profit. On an after-tax basis, the company recorded a profit, compared to last year's hefty loss, due to the absence of prior year's loss from discontinued operations. Separately, Prudential announced its 2022 first interim dividend of 5.74 US cents per ordinary share, which will be paid on September 27.
Follow RTT